ArQule, Inc.
19 Presidential Way
Woburn
Massachusetts
01801
United States
Tel: 781-994-0300
Fax: 781-376-6019
Website: http://www.arqule.com/
Email: Info@arqule.com
363 articles about ArQule, Inc.
-
ArQule Announces Pricing of $90 Million Public Offering of Common Stock
6/25/2019
ArQule, Inc. announced the pricing of an underwritten public offering of 9,250,000 shares of its common stock at a price to the public of $9.75 per share.
-
ArQule Announces Commencement of Proposed Public Offering of Common Stock - June 24, 2019
6/24/2019
ArQule, Inc. announced that it has commenced an underwritten public offering, subject to market and other conditions, to issue and sell shares of its common stock.
-
ArQule to Present at the BMO Prescriptions for Success Healthcare Conference on June 25, 2019
6/18/2019
ArQule, Inc. announced that Marc Schegerin, Chief Financial Officer and Head of Strategy, will present at the BMO Prescriptions for Success Healthcare Conference on June 25, 2019 at 8:00 a.m. ET at the The Mandarin Oriental New York, New York.
-
ArQule Announces Preliminary Results from Its Phase 1/2 Study of Miransertib (ARQ 092), in Patients with PIK3CA-related Overgrowth Spectrum (PROS) and Proteus syndrome (PS) in an Oral Presentation
6/17/2019
Encouraging preliminary safety and clinical activity data confirm miransertib’s potential for treating PS and PROS patients
-
ArQule Announces Clinical Proof-of-Concept Data from Ongoing Phase 1 Study of Reversible BTK Inhibitor, ARQ 531, in Patients with Relapsed/Refractory Hematologic Malignancies at the 2019 EHA Annual Meeting
6/14/2019
ArQule, Inc. announced preliminary results from the Company’s phase 1 dose escalation study for ARQ 531, an orally bioavailable, potent and reversible dual inhibitor of both wild type and C481S-mutant Bruton’s tyrosine kinase in patients with relapsed or refractory hematologic malignancies at the 2019 European Hematology Association Annual Meeting in Amsterdam, the Netherlands.
-
ArQule Announces Oral Presentation for its Pan-AKT Inhibitor, Miransertib, at the 2019 European Society of Human Genetics (ESHG) Conference
6/10/2019
Presentation highlights preliminary results from phase 1/2 study of miransertib in patients with PIK3CA-related Overgrowth Spectrum (PROS) and Proteus Syndrome (PS)
-
ArQule to Present Clinical Data for its BTK Inhibitor, ARQ 531, at the 24th Congress of the European Hematology Association (EHA)
6/7/2019
ArQule, Inc. announced that it will present clinical data from the company-sponsored phase 1 dose escalation study on its BTK inhibitor, ARQ 531, for the treatment of relapsed or refractory B-cell lymphoid malignancies in a poster presentation at the 24th Congress of European Hematology Association (EHA), held from June 13-16, 2019 in Amsterdam.
-
ArQule to Present at the Jefferies 2019 Healthcare Conference on June 6, 2019
5/30/2019
ArQule, Inc. announced that Paolo Pucci, Chief Executive Officer, Peter Lawrence, President and Chief Operating Officer, and Marc Schegerin, Chief Financial Officer and Head of Strategy, will present at the Jefferies 2019 Healthcare Conference on June 6, 2019 at 11:30 a.m. ET at the Grand Hyatt in New York City.
-
ArQule to Present at the 20th Annual B. Riley FBR Institutional Investor Conference on May 22, 2019
5/15/2019
ArQule, Inc. announced that Dr. Marc Schegerin, Chief Financial Officer and Head of Strategy, will present at the 20th Annual B. Riley FBR Institutional Investor Conference on May 22, 2019 at 9:30 a.m. PT at the Beverly Hilton in Beverly Hills, CA.
-
ArQule to Present at the 2019 RBC Capital Markets Global Healthcare Conference on May 21, 2019
5/14/2019
ArQule, Inc. announced that Paolo Pucci, Chief Executive Officer, and Dr. Brian Schwartz, Chief Medical Officer and Head of Research and Development, will present at the 2019 RBC Capital Markets Global Healthcare Conference on May 21, 2019 at 3:35 p.m. ET at the InterContinental New York Barclay in New York City.
-
ArQule to Present at the Bank of America Merrill Lynch 2019 Health Care Conference on May 15, 2019
5/8/2019
ArQule, Inc. announced that Peter Lawrence, President and Chief Operating Officer, and Dr. Marc Schegerin, Chief Financial Officer and Head of Strategy, will present at the Bank of America Merrill Lynch 2019 Health Care Conference on May 15, 2019 at 3:15 p.m. PT at the Encore Hotel in Las Vegas, NV.
-
ArQule Reports First Quarter 2019 Financial Results
5/1/2019
ArQule, Inc. announced its financial results for the first quarter, 2019.
-
Sinovant Sciences Announces Approval of Derazantinib’s Clinical Trial Application by the China National Medical Products Administration
4/30/2019
Chinese registrational clinical trial for derazantinib to begin in 2H 2019
-
ArQule Announces Management Team Changes
3/15/2019
ArQule, Inc. announced that Robert Weiskopf, Senior Vice President, Chief Financial Officer and Treasurer, has decided to retire effective March 29 of this year.
-
ArQule to Present at Oppenheimer’s 29th Annual Healthcare Conference on March 20, 2019
3/13/2019
ArQule, Inc. announced that Peter Lawrence, President and Chief Operating Officer, and Brian Schwartz, MD, Chief Medical Officer and Head of Research and Development, of ArQule will present at Oppenheimer’s 29th Annual Healthcare Conference on March 20, 2019 at 10:20 a.m. ET at the Westin New York Grand Central in New York City.
-
ArQule to Participate in the 31st Annual ROTH Conference on March 17-19, 2019
3/11/2019
ArQule, Inc. announced that Paolo Pucci, Chief Executive Officer, and Marc Schegerin, Senior Vice President and Head of Strategy, Finance and Communication, will participate in the 31st Annual ROTH Conference on March 17-19, 2019 in Dana Point, California.
-
ArQule Announces Publication of Clinical Data with Miransertib in Proteus Syndrome
2/25/2019
Data support miransertib as a potential first systemic treatment for individuals affected by Proteus syndrome
-
ArQule to Report Fourth Quarter and Full Year 2018 Financial Results on March 7, 2019
2/21/2019
ArQule, Inc. announced it will report financial results for the fourth quarter and full year of 2018 before the market opens on Thursday, March 7, 2019.
-
ArQule to Present at the 8th Annual Leerink Partners Global Healthcare Conference on February 28, 2019
2/21/2019
ArQule, Inc. announced that Paolo Pucci, Chief Executive Officer, and Brian Schwartz, M.D., Chief Medical Officer and Head of Research and Development, of ArQule will present at the 8th Annual Leerink Partners Global Healthcare Conference on February 28, 2019, at 11:30 a.m. ET at the Lotte New York Palace in New York City.
-
Basilea Announces Collaboration to Study Derazantinib and Atezolizumab (Tecentriq®) in Urothelial Cancer
1/24/2019
Basilea Pharmaceutica Ltd. announced today that it entered into a collaboration with Roche (SIX: RO, ROG) to explore a combination of derazantinib (BAL087) and Roche’s PD-L1-blocking immune-checkpoint inhibitor, atezolizumab (Tecentriq®), in patients with urothelial cancer. Basilea expects to start a biomarker-driven multi-cohort phase 1/2 study in mid-2019.